ABSTRACT -Ullrich congenital muscular dystrophy (UCMD), due to mutations in the collagen VI genes, is an autosomal recessive form of CMD, commonly associated with distal joints hyperlaxity and severe course. A mild or moderate involvement can be occasionally observ e d . Objective: To evaluate the clinical picture of CMD patients with Ullrich phenotype who presented decreased or absent collagen VI immunoreactivity on muscular biopsy. Results: Among 60 patients with CMD, two had no expression of collagen V and their clinical involvement was essentially diff e rent: the first (3 years of follow-up) has mild motor difficulty ; the second (8 years of follow-up) never acquired walking and depends on ventilatory support. A molecular stud y, perf o rmed by Pan et al. at the Thomas Jefferson University, demonstrated in the first a known mutation of Bethlem myopathy in COL6A1 and in the second the first dominantly acting mutation in UCMD and the first in COL6A1, previously associated only to Bethlem myopathy, with benign course and dominant inheri t a n c e . Conclusion: Bethlem myopathy should be considered in the diff e rential diagnosis of UCMD, even in patients without fingers contractures; overlap between Ullrich and Bethlem phenotypes can be supposed.
Bethlem myopathy is a dominantly inherited diso rder caused by mutations in the three genes of collagen VI, i.e. COL6A1 (21 q22.3), COL6A2 (21 q22. 3) and COL6A3 (2 q37) 1 -4 . Although Bethlem myopathy is clinically heterogeneous, most of patients have benign course. The onset may be in the neonatal period, childhood or adolescence and contracture s of fingers, elbows and ankles joints re p resent a hallmark of this phenotype 3 -5 . In addition, from 2001, the deficiency of collagen VI in muscle has been associated with Ullrich scleroatonic congenital muscular d y s t rophy (UCMD) that is caused by diff e rent types of recessive and dominantly acting mutations in the same three collagen VI genes 4 , 6 -8 . UCMD is clinically less heterogeneous than Bethlem myopathy; howev e r, although the majority of patients have the classic severe form that is characterized by neonatal muscle weakness, proximal joint contractures, hyperlaxity of the distal joints and severe course 4 , milder patients have now been re p o rt e d 9 . Both, Ullrich and Bethlem phenotypes are linked to the COL6A1, COL6A2 or COL6A3 genes, encoding respectively the alpha 1, alpha 2 and alpha 3 chains of collagen VI, and show clinical a n d genetic heterogeneity; there f o re mutation detection in essential in these disorders for allowing the correct diagnosis, the establishment of prognosis and an accurate genetic counseling.
For emphasizing this clinical and genetic heterog e n e i t y, we re p o rt on two patients with distal joint h i p e r l a x i t y, the first with a mild to moderate myopathic phenotype including joint hyperlaxity and the second with a severe Ullrich phenotype. In both, a molecular analysis was perf o rmed at the Thomas J e fferson University, Philadelphia, by Pan et al. 7 a n d revealed in the first a dominantly acting mutat i o n in the COL6A1 gene, that has not been desc r i b e d yet, and in the second a heterozygous in-fram e deletion in the COL6A1 that has been pre v io u s l y described in Bethlem myopathy [10] [11] .
METHOD
Sixty children with clinical and histopathological d i a gnosis of congenital muscular dystrophy (CMD) had their muscle samples evaluated immunohistochemically by means of immunofluorescency or immunoperoxidase m ethods, utilizing antibodies for dystrophin (C-term i n a l ) , m e rosin (80 Kda and 300 Kda), sarcoglycans ( , , y and -SGs) and dystroglicans ( -DG and -D G ) 1 2 . Among t h e m , 7 presented marked distal hyperlaxity and had their muscle samples also tested for collagen VI immunore a ctivity using Hybridoma Bank antibody, code 5C6,1/100. In two patients (Cases 1 and 2) collagen VI immunore a ctivity was absent.
CASES
Case 1 -A 4 year-9 month-old male was born at term following an uneventful pregnancy from non consanguineous parents who had already two healthy children. A t b i rth, the boy presented bilateral hip dislocation that was treated by the pediatrician and orthopedist. Motor development was mildly delayed: the child acquired supported walking by 15 months of age and unsupported walking by 21 months of age. From the age of two y e a r s , f requent falls and a difficulty for running and climbing stairs were noted by the parents and other relatives. L a nguage and mental development were normal. Our first examination at 4 years of age revealed, a mild to moderate difficulty for getting up from the floor, a mild proximal weakness of the four limbs (MRC 4), a marked generalized hypotonia, as well as a striking and widespre a d joint hypere x t e n s i b i l i t y. Deep tendon reflexes were hypoactive. On physical examination lumbar lord o s i s and a few small areas of abnormal hypochromic pigmentation in the skin of the lower limbs were noted. Seru m c reatine kinase levels were two-fold increased and elect romyography denoted abnormal myopathic pattern of muscle discharges. A muscle biopsy was perf o rmed at 5 years and 2 months of age and revealed mild to moderate dystrophic changes re p resented by size fiber variabilit y, moderate perimysial fibrous infiltration, mild endomysial fibrous infiltration, a scarce fatty deposition and some necrotic fibers. Cardiac evaluation was normal. A f t e r a follow-up of 39 months, the course can be considere d slowly pro g ressive as we observed a worsening of pro ximal muscle weakness (MRC 3 to 4) and the installation of mild distal weakness (MRC 4). The joint hyperlaxity persists and the boy did not develop any joint contracture. A molecular study of the patient's DNA was done at the Department of Dermatology and Cutaneous Biology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, by Pan et al. 7 and demonstrated a Bethlem myopathy heterozygous in-frame deletion in the COL6A1 gene, that had been previously desc r i b e d 1 0 , 1 1 . The p a t i e n t 's father has normal posture, mus- Table 1 . Immunohistochemical analysis of the muscle samples of the two patients.
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cular strength and tendon reflexes but presents moderate hyperlaxity of both thumbs, the left hand fingers and the left e l b o w. The analysis of his DNA did not re v e a l any mutation.
Case 2 -A 6-year-old boy was born at term following an uneventful pregnancy from non consanguineous p a rents who had already two healthy children. The child presented from birth severe congenital hypotonia and generalized muscle weakness with proximal pre d o m inance. Motor development was delayed: he sits without support by the age of one year and never acquire d independent walking. Language and mental development were normal. From the second year of life he gradually developed elbows and knees contractures. Our first examination at 6 years of age revealed decre a s e d muscular strength [score of 3 and 2, following the Medical Resource Council (MRC) scale, respectively in the distal and proximal segments of the 4 limbs] widespre a d muscular hypotonia and hypotro p h y, distal joints hyperlaxity, as well as absent deep tendon reflexes. We n o ted a mild ankles pro t rusion which the parents re f e rre d as more pronounced in the past years. The mother consid e red, after being inquired, that the child has hyperh id rosis when compared to his two normal older siblings. C a rdiac evaluation was normal. Serum creatine k i n a s e levels were normal and electromyography revealed abn o rmal myopathic pattern of muscle discharges. The f i r s t muscle biopsy, perf o rmed at the age of 6 years, showed moderate size fiber variability, and mild to moderate perimysial as well as endomysial fibrous infiltration. A second biopsy was perf o rmed at 9 years of age and evidentiated marked worsening of the former aspects and an additional accentuated fatty deposition, as well as some necrotic fibers. Immunohistochemical analysis with d i ff e rent antibodies was done (Table 1 ) and showed no collagen VI immunoreactivity (Fig 1) . In a previous stud y 1 3 , the patient's muscle sample had also been analysed for laminins 1, 1, 2 and 1 chains immunore a c t i v i t y. The result was normal, i.e. negative immunomarcation for 1 laminin chain, striking immunomarcation for 1 and 1 laminin chains and a little less pronounced imm u n o m a rcation for 2 laminin chain. Along the 8 years of follow-up, the boy manifested a pro g ressive worsening, that was characterized by an accentuation of the h i p o t rophy and of the contractures which became wides p read, as well as by the installation of scoliosis. Curre n t l y, the boy is 14-year-old and depends on ventilatory support from 11 years of age. A molecular analysis w a s p e rf o rmed at the Department of Dermatology and Cutaneous Biology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, by Pan et al. 7 and revealed a de novo in-frame heterozygous deletion of the COL6A1 gene.
DISCUSSION
Collagen VI is a protein that provides a micro f ilamentous network in the extracellular matrix of the muscular tissue, as well as in other organs. It i s essential for the correct function of muscle fibers, maintaining its structural integrity. An animal model of human Bethlem myopathy was already described and the details about the composition and the role of collagen VI have been widely discussed 3 .
Bethlem myopathy and Ullrich CMD result fro m molecular changes in each one of the three genes encoding collagen VI. The exact mechanism by which collagen VI leads to the myopathy is not p e rfectly clear. Recently, a possible mitochondria l dysfunction in myofibers has been implicated in this m e c h a n i s m 1 4 . According to Mercuri et al. 1 5 , collagen VI involvement is associated to molecular c h a nges in collagen VI genes in near to 40% of the C M D patients with Ullrich phenotype. In addition, there a re re p o rts of patients with low collagen VI re a c t ivity without mutations in collagen VI genes 1 5 , as well as of patients with mutations in collagen VI genes without changes in collagen VI re a c t i v i t y 1 6 , t h e re f o redocumenting the genetic hetero g e n e ity of Ullrich phenotype. Although the role of collagen VI seems be excluded in a number of cases 15 , Ishikawa et al. 1 7 recently considered that in patients with Ullrich phenotye who have no mutations in the collagen VI genes and there f o re a normal amount of Collagen VI in the interstitium, a primary a b n o rmality of other not yet identified molecules could cause a failure of collagen VI to anchor the basal lamina to the interstitium.
The first description of Bethlem myopathy was re f e rred by Bethlem & van Wi j n g a a rd e n 1 8 , who in 1976 re p o rted 28 patients from three families with an autosomal dominant, benign and slowly prog ressive myopathy. The most characteristic aspect of Bethlem myopathy is the occurrence of early c o nt r a c t u res of the interphalangeal joints and the elbows. Merlini et al. 1 9 considered that the fingers c o n t r a c t u resare the hallmark of Bethlem myopat h y. Clinical presentation and age of onset are highly variable 3 , 5 and although the clinical course of the disease is thought to be benign, some re p o rt s emphasize that Bethlem myopathy can be slowly p ro g ressive and can culminate in wheelchair use . Histopathological findings were either nonspecific or compatible with dystrophic changes and cre atine kinase levels can be normal or mildly elevate d 3 . Collagen VI can be norm a l 3 . As diff e rent kinds of mutations have been found in Bethlem myopathy, t h e reare attempts of establishing genotype/phenotype correlation in Bethlem patients and some data indicate that large deletions and mutations inside the triple-helical collagen VI monomer helix f o rmed by the three collagenous polypeptides 1 , 2 and 3 are associated with a more severe phenotype than those occurring in the N-terminal globular region 4 .
The first report of Ullrich phenotype occurred in 1930 by Ullrich 2 3 who named it scleroatonic form of CMD and until 2002 only recessive mutations had been described in patients with UCMD 3 , 6 . In 2003, the first dominantly acting mutation in the COL6A1 gene was found in one of our Brazilian p atients who we are now re p o rt i n g 7 and re c e n t l y m o re three patients with a dominantly acting mutation in the COL6A1 gene were published 8 . Bes i d e the genetic hetero g e n e i t y, UCMD also exhibits clinical hetero g e n e i t y 4 , 9 , 1 5 -1 6 , 2 4 that is not related to each of the 3 loci, but can be associated to the d e g ree of the deficiency of collagen VI in muscle o r c u l t u red fibro b l a s t s 1 6 . A complete deficiency has been observed in the severe cases while the milder ones show a partial deficiency 1 6 . However, the majority of patients have a severe involvement that includes scoliosis, failure to thrive, and early and s e v e re re s p i r a t o ry impairment by the end of the first decade of life 15 . Mildly affected patients can be related to mutations leading to a partial deficiency of collagen VI 9, 16 .
The present re p o rt intends to emphasize the wide spectrum of phenotypes that can be associated to collagen VI deficiency. Both patients have marked distal hyperlaxity, and histopathological d y s t rophic pattern, but clinical involvement was essentially diff e rent: the first (with 3 years and 4 months of follow-up) acquired independent walking and shows a mild difficulty for running and climbing; the second (with 8 years of follow-up) never acquired independent walking and needs i n t e rmittent ventilatory support from the beginning of the second decade of life. A molecular study of both patients was perf o rmed by Pan et al. 7 at the Thomas Jefferson University and demonstrated in each one a diff e rent type of deletion of COL6A1 gene: in the first a heterozygous in-frame deletion in the COL6A1 that has been pre v i o u s l y described in Bethlem myopathy 1 0 , 1 1 and in the second a dominantly acting mutation in the COL6A1 gene, that has not been described yet. This gene had been previously associated only to Bethlem myopathy and from 2003 is associated also to UCMD, as well as with a particular aspect of ossification of the posterior longitudinal ligament of s p ine in some subjects 25 .
In Patient 1, the absence of contractures, the marked joint hyperlaxity, and the dystrophic patt e rnfound on muscle biopsy had been supposed b y us as suggestive of a non specific mero s i n -p o s i t i v e CMD diagnosis. The result of the molecular analysis denoting a previously described Bethlem myopathy heterozygous in-frame deletion in the C O L 6 A 1 gene 10, 11 indicates that the boy, currently young, will probably manifest contractures and develop along the follow-up a phenotype more compati-ble with Bethlem myopathy. However, as his foll o wup is now completing three years, he can be consid e red an atypical case. During the 100th Euro p e a n N e u romuscular Center (ENMC) international works h o p 4 , Muntoni considered that joint laxity, aff e c ting especially the knees and elbows, can be a common finding at presentation and diseappears along the years. In the same opport u n i t y 4 , this author re p o rted a case particularly coincidental to ours including by the presence of bilateral hip dislocation. His patient, currently aged 28, has also congenital torticollis, a finding that has been commonly described 3 . In addition, the dystrophic changes on the muscular biopsy, previously considere d non compatible with Bethlem myopathy 2 6 , have been found so frequently as the non specific chang e s 3 . However, even considering that the lack of c o n t r a c t u res and the dystrophic changes on muscular biopsy, as observed in our Patient 1, have been re p o rted in patients with confirmed molecular diagnosis of Bethlem myopathy 3 , 4 such findings at p resentation can not be considered typical. In fact, Jobsis et al.
2 0 followed-up 23 children and 36 adult patients with Bethlem myopathy and found that nearly all children exhibit weakness or contractures during the first two years of life. In addition, a c c o rding to Bertini and Pepe 5 , muscle biopsy fro m Bethlem cases shows non specific changes and an i n c rease of endomysial connective tissue is rare l y o b s e rved. Merc u ry et al. 2 1 re p o rted that the degre e of muscle involvement varies according to the deg ree of motor impairment. There f o re in Patient 1 a less amount of muscle changes would be expected. In addition, as in our patient was found a hete rozygous in-frame deletion of 18 aminoacids somewhat downstream in the triple-helical domain, a result of exon 14 skipping in the COL6A1 gene 7 , we could theoretically expect a more severe clinical involvement. The patients already re p o rted with a type of mutation similar to that observed in o u r patient have either a typical clinical picture with finger contracture s 1 0 or a severe course when comp ared to that of other reported Bethlem myopathy f a m i l i e s 1 1 . In one familiy one of the affected members had lost the deambulation at the age of 35 years and another member had developed Achilles' tendons bilateral shortening and finger contract u res from 7 years of age 1 1 . Finally, as muscle immun o h i s t o c h e m i s t ry with Col VI antibodies can be normal in the muscle 3 , being detected only by fib roblast culture, that is not a routine pro c e d u re, t h e description of the clinical findings of our Patient 1 intends to emphasize that Bethlem myopathy should be included among the diff e rential diagnosis of merosin-positive CMD. Besides this, in sporadic patients with clinical and histopathological findings suggestive of merosin-positive CMD, who also manifest joint hyperlaxity, a molecular analysis looking for Bethlem mutations is recommended.
Patient 2 has a classic severe form of UCMD and re p resented the first example of UCMD with a hete rozygous in-frame deletion in COL6A1 7 , there f o re i n c reasing the already marked genetic hetero g e n eity observed in this form of CMD. Ve ry recently more t h ree patients with dominant mutations have been described, all manifesting severe phenotype characterized by marked restriction of re s p i r a t o ry function, scoliosis and lack of independent ambulation in one of them 8 . According to Baker et al. 8 , these new genetic data in UCMD 7 -8 highlighted the necessity of a careful mutation investigation for pro v i ding an accurate genetic counseling advice. Patient 2 was the only who presented a typical severe Ullrich phenotype among around 80 childrens with clinical and histopathological diagnosis of CMD, including 34 typical MD-CMD cases, who we have attended and followed-up since 1990 at our institution. There f o re, although Muntoni and Vo i t 9 h a v e re f e rred that UCMD is probably the second most frequent variant of CMD, it is our impression that UCMD is not so common among Brazilian patients.
In conclusion, the new molecular data seem suggest that new phenotypes linked to collagen VI unit and particularly to COL6A1 gene can be identified in a next future, so defining if Ullrich and Bethlem phenotypes are independent entities or, as re p o rted by Bertini and Pepe 5 , re p re s e n t an overlap between the clinical phenotypes and the molecular defects. A probable overlap between UCMD, Bethlem myopathy and Ehlers-Danlos synd romes has been the focus of recent re s e rc h e s 4 , 9 , 2 7 . The search for new mutations in the three genes o f collagen VI unit in all patients with typical Ullrich phenotype, typical Bethlem phenotype and non specific merosin-positive CMD phenotype associated to joint hyperlaxity, as well as the description of each phenotype associated to the new mutations re p resent an enormous field of re s e a rches in infantile myology, particularly for clarifying undefined merosin-positive CMD forms. In addition, new molecular and clinical descriptions are needed for reaching a better understanding of the ro l e of collagen VI in the muscle function and its correlation with the other collagen units.
